156 related articles for article (PubMed ID: 30624936)
1. Discovery of ( R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies.
Wang HL; Andrews KL; Booker SK; Canon J; Cee VJ; Chavez F; Chen Y; Eastwood H; Guerrero N; Herberich B; Hickman D; Lanman BA; Laszlo J; Lee MR; Lipford JR; Mattson B; Mohr C; Nguyen Y; Norman MH; Pettus LH; Powers D; Reed AB; Rex K; Sastri C; Tamayo N; Wang P; Winston JT; Wu B; Wu Q; Wu T; Wurz RP; Xu Y; Zhou Y; Tasker AS
J Med Chem; 2019 Feb; 62(3):1523-1540. PubMed ID: 30624936
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.
Pettus LH; Andrews KL; Booker SK; Chen J; Cee VJ; Chavez F; Chen Y; Eastwood H; Guerrero N; Herberich B; Hickman D; Lanman BA; Laszlo J; Lee MR; Lipford JR; Mattson B; Mohr C; Nguyen Y; Norman MH; Powers D; Reed AB; Rex K; Sastri C; Tamayo N; Wang P; Winston JT; Wu B; Wu T; Wurz RP; Xu Y; Zhou Y; Tasker AS; Wang HL
J Med Chem; 2016 Jul; 59(13):6407-30. PubMed ID: 27285051
[TBL] [Abstract][Full Text] [Related]
3. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
4. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
5. Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.
Wang X; Blackaby W; Allen V; Chan GKY; Chang JH; Chiang PC; Diène C; Drummond J; Do S; Fan E; Harstad EB; Hodges A; Hu H; Jia W; Kofie W; Kolesnikov A; Lyssikatos JP; Ly J; Matteucci M; Moffat JG; Munugalavadla V; Murray J; Nash D; Noland CL; Del Rosario G; Ross L; Rouse C; Sharpe A; Slaga D; Sun M; Tsui V; Wallweber H; Yu SF; Ebens AJ
J Med Chem; 2019 Feb; 62(4):2140-2153. PubMed ID: 30715878
[TBL] [Abstract][Full Text] [Related]
6. Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors.
Wurz RP; Sastri C; D'Amico DC; Herberich B; Jackson CLM; Pettus LH; Tasker AS; Wu B; Guerrero N; Lipford JR; Winston JT; Yang Y; Wang P; Nguyen Y; Andrews KL; Huang X; Lee MR; Mohr C; Zhang JD; Reid DL; Xu Y; Zhou Y; Wang HL
Bioorg Med Chem Lett; 2016 Nov; 26(22):5580-5590. PubMed ID: 27769621
[TBL] [Abstract][Full Text] [Related]
7. The discovery and optimization of aminooxadiazoles as potent Pim kinase inhibitors.
Wurz RP; Pettus LH; Jackson C; Wu B; Wang HL; Herberich B; Cee V; Lanman BA; Reed AB; Chavez F; Nixey T; Laszlo J; Wang P; Nguyen Y; Sastri C; Guerrero N; Winston J; Lipford JR; Lee MR; Andrews KL; Mohr C; Xu Y; Zhou Y; Reid DL; Tasker AS
Bioorg Med Chem Lett; 2015 Feb; 25(4):847-55. PubMed ID: 25599837
[TBL] [Abstract][Full Text] [Related]
8. The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors.
Wang HL; Cee VJ; Chavez F; Lanman BA; Reed AB; Wu B; Guerrero N; Lipford JR; Sastri C; Winston J; Andrews KL; Huang X; Lee MR; Mohr C; Xu Y; Zhou Y; Tasker AS
Bioorg Med Chem Lett; 2015 Feb; 25(4):834-40. PubMed ID: 25597005
[TBL] [Abstract][Full Text] [Related]
9. Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.
Burger MT; Nishiguchi G; Han W; Lan J; Simmons R; Atallah G; Ding Y; Tamez V; Zhang Y; Mathur M; Muller K; Bellamacina C; Lindvall MK; Zang R; Huh K; Feucht P; Zavorotinskaya T; Dai Y; Basham S; Chan J; Ginn E; Aycinena A; Holash J; Castillo J; Langowski JL; Wang Y; Chen MY; Lambert A; Fritsch C; Kauffmann A; Pfister E; Vanasse KG; Garcia PD
J Med Chem; 2015 Nov; 58(21):8373-86. PubMed ID: 26505898
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
Bataille CJ; Brennan MB; Byrne S; Davies SG; Durbin M; Fedorov O; Huber KV; Jones AM; Knapp S; Liu G; Nadali A; Quevedo CE; Russell AJ; Walker RG; Westwood R; Wynne GM
Bioorg Med Chem; 2017 May; 25(9):2657-2665. PubMed ID: 28341403
[TBL] [Abstract][Full Text] [Related]
11. New potent and selective inhibitor of Pim-1/3 protein kinases sensitizes human colon carcinoma cells to doxorubicin.
Moreau P; Dezhenkova LG; Anizon F; Nauton L; Thery V; Liang S; Kaluzhny DN; Shtil AA
Anticancer Agents Med Chem; 2014; 14(9):1228-36. PubMed ID: 25175798
[TBL] [Abstract][Full Text] [Related]
12. Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors.
More KN; Hong VS; Lee A; Park J; Kim S; Lee J
Bioorg Med Chem Lett; 2018 Aug; 28(14):2513-2517. PubMed ID: 29871845
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological activities of 4-substituted pyrrolo[2,3-a]carbazole Pim kinase inhibitors.
Giraud F; Akué-Gédu R; Nauton L; Candelon N; Debiton E; Théry V; Anizon F; Moreau P
Eur J Med Chem; 2012 Oct; 56():225-36. PubMed ID: 22982527
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
Martínez-González S; Rodríguez-Arístegui S; Gómez de la Oliva CA; Hernández AI; González Cantalapiedra E; Varela C; García AB; Rabal O; Oyarzabal J; Bischoff JR; Klett J; Albarrán MI; Cebriá A; Ajenjo N; García-Serelde B; Gómez-Casero E; Cuadrado-Urbano M; Cebrián D; Blanco-Aparicio C; Pastor J
Eur J Med Chem; 2019 Apr; 168():87-109. PubMed ID: 30802730
[TBL] [Abstract][Full Text] [Related]
15. Pim kinases in hematological malignancies: where are we now and where are we going?
Mondello P; Cuzzocrea S; Mian M
J Hematol Oncol; 2014 Dec; 7():95. PubMed ID: 25491234
[TBL] [Abstract][Full Text] [Related]
16. Rational Design of a Potent Pan-Pim Kinases Inhibitor with a Rhodanine-Benzoimidazole Structure.
Sawaguchi Y; Yamazaki R; Nishiyama Y; Sasai T; Mae M; Abe A; Yaegashi T; Nishiyama H; Matsuzaki T
Anticancer Res; 2017 Aug; 37(8):4051-4057. PubMed ID: 28739687
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and structure activity relationship of potent pan-PIM kinase inhibitors derived from the pyridyl carboxamide scaffold.
Nishiguchi GA; Burger MT; Han W; Lan J; Atallah G; Tamez V; Lindvall M; Bellamacina C; Garcia P; Feucht P; Zavorotinskaya T; Dai Y; Wong K
Bioorg Med Chem Lett; 2016 May; 26(9):2328-32. PubMed ID: 26995528
[TBL] [Abstract][Full Text] [Related]
18. Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.
Riggs JR; Elsner J; Cashion D; Robinson D; Tehrani L; Nagy M; Fultz KE; Krishna Narla R; Peng X; Tran T; Kulkarni A; Bahmanyar S; Condroski K; Pagarigan B; Fenalti G; LeBrun L; Leftheris K; Zhu D; Boylan JF
J Med Chem; 2019 May; 62(9):4401-4410. PubMed ID: 30998356
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.
Tao ZF; Hasvold LA; Leverson JD; Han EK; Guan R; Johnson EF; Stoll VS; Stewart KD; Stamper G; Soni N; Bouska JJ; Luo Y; Sowin TJ; Lin NH; Giranda VS; Rosenberg SH; Penning TD
J Med Chem; 2009 Nov; 52(21):6621-36. PubMed ID: 19842661
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
